Literature DB >> 12001199

Maternal uniparental isodisomy 10 and mosaicism for an additional marker chromosome derived from the paternal chromosome 10 in a fetus.

Monika Schlegel1, Alessandra Baumer, Mariluce Riegel, Ute Wiedemann, Albert Schinzel.   

Abstract

We report a case of maternal isodisomy 10 combined with mosaic partial trisomy 10 (p12.31-q11.1). Chromosome examinations from a CVS sample showed a karyotype 47,XX,+mar/46,XX [corrected]. The additional marker chromosome which was present in 6/25 interphase nuclei was shown by fluorescence in situ hybridization (FISH) to have been derived from a pericentromeric segment of chromosome 10. DNA analysis was performed from umbilical cord blood from the fetus after termination of the pregnancy at 18 weeks. The results showed that the two structurally normal chromosomes 10 were both of maternal origin, whereas the marker chromosome derived from the father. Autopsy of the fetus revealed hypoplasia of heart, liver, kidneys and suprarenal glands, but, apart from a right bifid ureter, no structural organ abnormalities. This fetus represents the second reported instance of a maternal uniparental disomy (UPD) 10. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001199     DOI: 10.1002/pd.337

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  2 in total

1.  Redefining the risks of prenatally ascertained supernumerary marker chromosomes: a collaborative study.

Authors:  M D Graf; L Christ; J T Mascarello; P Mowrey; M Pettenati; G Stetten; P Storto; U Surti; D L Van Dyke; G H Vance; D Wolff; S Schwartz
Journal:  J Med Genet       Date:  2006-08       Impact factor: 6.318

2.  Causal variants screened by whole exome sequencing in a patient with maternal uniparental isodisomy of chromosome 10 and a complicated phenotype.

Authors:  Niu Li; Y U Ding; Tingting Yu; Juan Li; Yongnian Shen; Xiumin Wang; Qihua Fu; Yiping Shen; Xiaodong Huang; Jian Wang
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.